Antidepressants and Weight on a GLP-1: SSRIs, SNRIs, Wellbutrin, and What the Evidence Actually Shows

Patients arrive at this question from two directions. Some are already on an SSRI, SNRI, or Wellbutrin and starting a GLP-1. Others are on a GLP-1 and noticing weight regain or mood changes that prompt antidepressant questions. The published evidence is more specific than the Reddit threads. The 2018 Gafoor cohort of 294,719 UK primary-care patients^[1] found a 21% higher rate of clinically significant weight gain in antidepressant users overall — but the effect varies enormously by drug, with paroxetine and mirtazapine on one end and bupropion (which causes 7-10% weight loss)^[4] on the other. None of the FDA labels for Wegovy, Ozempic, Mounjaro, Zepbound, or Foundayo flag pharmacokinetic interactions with any antidepressant beyond the general gastric-emptying note. And the 2024 EMA PRAC review and the Wang 2024 Nature Medicine cohort of 1.8 million patients^[11] both concluded that there is no causal link between GLP-1s and suicidal ideation. Here is the verified evidence map.

Why this comes up so often

Depression and obesity are bidirectionally linked. The landmark 2010 meta-analysis by Luppino and colleagues^[10] pooled 15 longitudinal studies covering 58,745 participants and reported that obesity at baseline increased the odds of incident depression by 55% (OR 1.55, 95% CI 1.22-1.98, p<0.001), and that depression at baseline increased the odds of incident obesity by 58%. The relationship runs both ways and is stronger for clinical depression than for depressive symptoms. The implication is that any clinic seeing patients with obesity is also seeing a population with substantially higher antidepressant prescribing prevalence than the general public, and the GLP-1 conversation has to meet that population where they are.

SSRIs and weight: the long-term picture

The strongest population-level evidence comes from Gafoor and colleagues^[1]. Their 2018 BMJ cohort followed 294,719 UK primary-care patients for 10 years and found that antidepressant users had an adjusted rate ratio of 1.21 (95% CI 1.19-1.22) for ≥5% weight gain compared to non-users (11.2 per 100 person-years vs 8.1 per 100 person-years). The 21% relative excess is real, but the absolute magnitude is modest, and the effect varies by drug.

Drug-by-drug, the published RCTs tell a more nuanced story:

• Paroxetine (Paxil) is consistently the worst SSRI for weight. Fava and colleagues^[2] compared fluoxetine, sertraline, and paroxetine over 26-32 weeks in 284 patients with major depressive disorder and found paroxetine produced significantly more ≥7% weight gain than the other two.
• Sertraline (Zoloft) showed a modest, statistically non-significant weight increase in the same trial. Most long-term cohort data classify sertraline as weight-neutral to mildly weight-positive.
• Fluoxetine (Prozac) has a paradoxical early-treatment weight loss signal that disappears with long-term use; the Fava trial showed it as essentially weight-neutral over 6-8 months.
• Citalopram (Celexa) and escitalopram (Lexapro). Maina and colleagues^[3] studied long-term SSRI weight effects in OCD treatment and reported greater weight gain with citalopram and escitalopram than with sertraline or fluoxetine. Magnitudes are modest but real.
• Mirtazapine (Remeron) is the antidepressant most reliably associated with weight gain — on the order of 1.4-3.6 kg in the first 6-8 weeks across multiple trials, plateauing after about 6-8 months. Mechanism is appetite stimulation through histamine H1 antagonism. Patients on mirtazapine starting a GLP-1 will sometimes notice the appetite tug-of-war directly.

SNRIs: less data, similar magnitude

The SNRI weight literature is less complete than the SSRI literature. Venlafaxine (Effexor) and duloxetine (Cymbalta) are generally classified as weight-neutral to mildly weight- positive long-term, with most weight effect at the higher doses used for treatment-resistant depression. Specific primary-source RCTs reporting weight as a primary endpoint for these drugs were not located by the verification subagent; we are flagging the SNRI section as moderate-evidence rather than well-characterized.

Bupropion: the antidepressant that causes weight loss

Bupropion (Wellbutrin) is mechanistically distinct from the SSRIs and SNRIs. It is a norepinephrine and dopamine reuptake inhibitor (NDRI) with no direct serotonergic activity. The weight effect is real, magnitude-significant, and well- documented in dedicated obesity trials.

Anderson and colleagues^[4] randomized 327 patients in a 48-week double-blind placebo-controlled trial of bupropion SR for weight loss. At 24 weeks the placebo arm had lost 5.0% of body weight, the bupropion SR 300 mg arm had lost 7.2% (p=0.0468), and the bupropion SR 400 mg arm had lost 10.1% (p<0.0001). At 48 weeks the sustained losses were −7.5% (300 mg) and −8.6% (400 mg). Croft and colleagues^[5] compared bupropion SR with sertraline in 360 patients with moderate-to-severe major depression and found that bupropion produced significantly less weight gain and significantly less sexual dysfunction.

The Contrave program extended this into FDA-approved obesity therapy by combining bupropion with naltrexone. Greenway and colleagues^[6] reported the COR-I trial in the Lancet in 2010 (n=1,742): patients on naltrexone 32 mg + bupropion 360 mg lost 6.1% of body weight vs 1.3% on placebo (p<0.0001), and 48% achieved ≥5% weight loss vs 16% on placebo. The COR-II trial^[7] (n=1,496) confirmed the magnitude at 28 and 56 weeks. The COR-BMOD trial^[8] (n=793) added intensive behavioral modification and reported −9.3% weight loss with Contrave + behavior modification vs −5.1% with placebo + behavior modification at 56 weeks.

For a patient on Wellbutrin who is starting a GLP-1, the practical implication is that the two effects are additive, not antagonistic. Wellbutrin is contributing to appetite suppression and potentially producing 5-8% weight loss on its own; the GLP-1 adds 10-20% on top. The combination is also the architecture behind Contrave (a single pill with both components), so it is not pharmacologically novel.

Vortioxetine and the “weight-neutral” class

Vortioxetine (Trintellix) is marketed as weight-neutral and cognition-preserving. Mahableshwarkar and colleagues^[9] studied vortioxetine in 600 adults with major depression and self-reported cognitive dysfunction, and the FDA-approved label confirms that vortioxetine had no significant weight impact in short-term studies or during the 6-month phase of long-term follow-up. For patients on a GLP-1 who need an antidepressant and are concerned about weight, vortioxetine and bupropion are the two most defensible choices on the basis of weight effects alone.

Pharmacokinetic interactions: what the FDA labels actually say

The verification subagent pulled the current FDA labels for Wegovy, Ozempic, Mounjaro, Zepbound, and Foundayo (orforglipron) directly from DailyMed on 2026-04-07. The bottom line:

• No specific antidepressant is listed in the contraindications or drug-interactions section of any GLP-1 label.
• All five labels contain the same gastric-emptying caveat: “[Drug] delays gastric emptying and may impact the absorption of concomitantly administered oral medications.” This is a general note about oral drug absorption, not an antidepressant-specific warning.
• No serotonin-syndrome warnings. There is no documented case of serotonin syndrome from a GLP-1 + SSRI combination; the FDA labels do not list this as a concern.
• Foundayo (orforglipron) is metabolized via CYP3A4and the label notes potential interactions with strong CYP3A4 inhibitors and inducers. Most antidepressants are not strong CYP3A4 modulators, but fluoxetine and fluvoxamine have moderate CYP enzyme effects worth flagging to the prescriber.

The headline practical implication: combining a GLP-1 with an SSRI, SNRI, bupropion, or vortioxetine does not require a dose adjustment, and there is no documented PK interaction in any of the FDA labels. The shared tradeoff is overlapping side effects: GLP-1 nausea and SSRI nausea both peak in the first 4-8 weeks, and patients starting both at once will sometimes have a worse tolerability period than patients starting either one alone. Staggering initiations by 4-8 weeks is a clinical workaround, not an FDA requirement.

The suicidality signal: what the EMA and a 1.8M-patient cohort actually found

In 2023 and 2024, scattered post-marketing reports of suicidal ideation in patients on semaglutide and liraglutide prompted the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) to open a formal review. The review covered 11 GLP-1 products including Ozempic, Wegovy, Saxenda, Victoza, and Trulicity. The PRAC published its outcome statement on April 11, 2024 concluding that “the available evidence does not support a causal association” between GLP-1 receptor agonists and suicidal or self-injurious thoughts and actions. No product information updates were required, and continued routine monitoring was recommended.

On the same question, Wang and colleagues^[11] published the largest real-world cohort to date in Nature Medicine in early 2024. They used the TriNetX EHR network and propensity-matched 240,618 patients with obesity (and replicated the analysis in 1,589,855 patients with type 2 diabetes) on semaglutide vs other anti-obesity medications. The hazard ratio for incident suicidal ideation in semaglutide-treated patients was 0.27 (a 73% relative reduction) for incident ideation and 0.44 (56% reduction) for recurrent ideation. The diabetes cohort replicated the finding. This is a large observational cohort, not an RCT, and observational designs cannot fully control for confounding by indication — but the direction is unambiguous, and the regulatory conclusion (no causal link) is consistent.

For a patient on an SSRI who is starting a GLP-1, the signal pattern is reassuring. The drugs do not interact pharmacokinetically, the GLP-1 has no convincing causal relationship with suicidality in either regulatory or real- world data, and the population-level signal is in the opposite direction. Mood symptoms that emerge after starting a GLP-1 should be evaluated in the same way as mood symptoms in any other patient — not attributed reflexively to the drug.

The Wellbutrin seizure caveat (relevant for Contrave users)

Bupropion lowers the seizure threshold and is contraindicated in patients with a history of seizure disorder, current or prior anorexia nervosa or bulimia, and abrupt withdrawal from alcohol, benzodiazepines, barbiturates, or antiepileptics. The Contrave label reports a clinical-trial seizure incidence of approximately 0.1% versus 0% on placebo. The risk is managed by adhering to the dose escalation schedule, dividing doses, avoiding high-fat meals (which increase peak concentrations), and not taking more than 2 tablets at once. Patients with active eating disorders should not be on Contrave or on bupropion monotherapy.

The practical decision tree

For a patient on an antidepressant who is starting a GLP-1:

• SSRI (sertraline, escitalopram, citalopram, fluoxetine): No PK interaction. Continue. Watch for additive nausea in the first 4-8 weeks; consider staggering dose escalations. Long-term weight effect is modest and unlikely to interfere with GLP-1 efficacy.
• Paroxetine or mirtazapine: No PK interaction with the GLP-1, but these two are the most weight-positive antidepressants in the literature. If the mood indication is flexible, discuss with the prescribing psychiatrist whether a switch to sertraline, vortioxetine, or bupropion might better align with the weight goal.
• SNRI (venlafaxine, duloxetine): No PK interaction. Continue. Less weight data than SSRIs.
• Bupropion (Wellbutrin): No PK interaction. Continue. Effects on weight are additive with the GLP-1, in the same direction. This is the antidepressant most aligned with the weight goal. Mind the seizure contraindications.
• Vortioxetine (Trintellix): Weight-neutral and no PK interaction. A defensible second-line choice if the patient needs both mood treatment and minimal weight effect.

For a patient on a GLP-1 who develops new depressive symptoms:

• The EMA and Wang 2024 evidence does not support attributing mood symptoms to the GLP-1 reflexively. Evaluate as you would in any patient.
• Bupropion or vortioxetine are first-line choices that minimize the antidepressant-induced weight signal.
• Sertraline is the most-studied and most-tolerated SSRI in the obesity-comorbid population.
• Avoid paroxetine and mirtazapine first-line in this population unless there is a specific reason (mirtazapine is sometimes used for the appetite stimulation in patients with cancer cachexia or anorexia, but obviously not in patients seeking weight loss).

Bottom line

• Population-level signal: Gafoor 2018 BMJ (n=294,719) showed antidepressant users have a 21% higher rate of ≥5% weight gain — but the effect varies enormously by drug.
• Worst weight offenders: mirtazapine, paroxetine.
• Roughly weight-neutral: sertraline, fluoxetine, vortioxetine, venlafaxine.
• Causes weight loss: bupropion (Wellbutrin) at 7-10% magnitude in dedicated trials, and the bupropion + naltrexone combination is FDA-approved as Contrave.
• FDA labels for Wegovy, Ozempic, Mounjaro, Zepbound, and Foundayo flag no antidepressant pharmacokinetic interactions beyond the general gastric-emptying caveat.
• Suicidality: the EMA PRAC April 2024 review and Wang 2024 Nature Medicine cohort (n=1.8M) both found no causal link between GLP-1s and suicidal ideation.
• Practical workaround: stagger antidepressant and GLP-1 dose escalations by 4-8 weeks to minimize additive nausea, even though there is no formal PK interaction.
• Bupropion contraindications (seizure disorder, eating disorder, abrupt sedative withdrawal) still apply when used as Wellbutrin or as Contrave.

Related research and tools

• Can you take phentermine with a GLP-1? — the related stimulant + GLP-1 question
• GLP-1 side effects: questions answered — the broader side effects map including mood
• GLP-1 nausea management — relevant for staggered antidepressant + GLP-1 starts
• GLP-1 drug interaction checker — lookup tool for any concomitant medication
• Switching between GLP-1 medications — relevant if mood symptoms emerge mid-therapy
• GLP-1 side effects: what trials actually showed — the broader trial AE picture

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about starting, stopping, or switching antidepressants should be made with a qualified prescribing clinician (typically a psychiatrist or primary care physician) who knows the patient's mental health history. Stopping an antidepressant abruptly can produce discontinuation syndrome and, in patients with severe depression, increase suicide risk. Every primary source cited here was independently verified against PubMed and FDA DailyMed on 2026-04-07 by a research subagent. The McIntyre 2024 JAMA Psychiatry meta-analysis on GLP-1s and psychiatric outcomes could not be independently verified and is excluded from this article.